Open access · OA
via Europe PMC
Pharmaceutical Strategies for Translating Klotho-Based Therapeutics: From Biologic Developability to Advanced Delivery Systems.
Zeng L, Chen X, Li Y, Xiong W.
Pharmaceutics · 2026
Abstract
Klotho is a longevity-associated and tissue-protective protein involved in mineral metabolism, oxidative stress, inflammation, fibrosis, cellular senescence(definition), and neurovascular homeostasis. However, nearly three decades after its discovery, no Klotho-based therapy has been approved, highlighting a translational gap that extends beyond biological validation. This review reframes Klotho translation as a pharmaceutical sciences challenge, focusing on how to convert Klotho into a druggable, manufacturable, deliverable, and clinically controllable therapeutic product. We summarize the isoform-specific properties of membrane-bound α-Klotho, soluble α-Klotho, and β-Klotho that are relevant to product design, and review the current clinical and preclinical landscape dominated by gene-, mRNA-, and antibody-based approaches. We further distinguish confirmed developability barriers, including renal handling and limited systemic persistence, from plausible risks common to macromolecular biologics, such as aggregation, chemical degradation, immunogenicity, and poor tissue penetration. Finally, we evaluate emerging delivery and formulation strategies, including viral and non-viral gene delivery, extracellular vesicles, hydrogels, ultrasound-targeted microbubbles, osmotic pumps, and long-acting protein engineering. An integrated roadmap combining molecular engineering, disease-specific delivery, pharmacokinetic/pharmacodynamic biomarkers, manufacturability assessment, and repeated-dose safety evaluation may help transform Klotho from a promising anti-aging molecule into a clinically viable biologic platform.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/pharmaceutics18091124
- Canonical
- link ↗
- Fetched
- 2026-10-11 MST
Cite this
APA
L, Z., X, C., Y, L., & W., X. (2026). Pharmaceutical Strategies for Translating Klotho-Based Therapeutics: From Biologic Developability to Advanced Delivery Systems. <em>Pharmaceutics</em>. https://doi.org/10.3390/pharmaceutics18091124
Vancouver
L Z, X C, Y L, W. X. Pharmaceutical Strategies for Translating Klotho-Based Therapeutics: From Biologic Developability to Advanced Delivery Systems. Pharmaceutics. 2026. doi:10.3390/pharmaceutics18091124.
BibTeX
@article{zeng2026Pharma,
title = {Pharmaceutical Strategies for Translating Klotho-Based Therapeutics: From Biologic Developability to Advanced Delivery Systems.},
author = {Zeng L and Chen X and Li Y and Xiong W.},
journal = {Pharmaceutics},
year = {2026},
doi = {10.3390/pharmaceutics18091124},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in nutrition 2026
Open access · OA
Urolithins in clinical translation: from gut microbial metabolites to precision interventions.
Frontiers in Nutrition 2026
Open access · CC-BY
Urolithins in clinical translation: from gut microbial metabolites to precision interventions
Journal of Stroke and Cerebrovascular Diseases 2025
Open access · CC-BY
Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment
Medicinal Research Reviews 2024
Open access · CC-BY
Targeting lysosomal quality control as a therapeutic strategy against aging and diseases
Frontiers in human neuroscience 2026
Open access · OA
Shared molecular mechanisms in aging and neurodegenerative diseases: from mechanistic insights to therapeutic strategies.
Innovation in Aging 2022
Open access · CC-BY